文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

评估负载WT1肽的树突状细胞疫苗(TLP0-001)联合S-1治疗标准化疗难治性晚期胰腺癌患者安全性与疗效的双盲随机对照临床试验

A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
PubMed 文献 · Trials · 2019-04-27

这是一项研究者发起的双盲对照试验,计划纳入185例对吉西他滨联合白蛋白结合型紫杉醇标准一线化疗难治或不耐受的不可手术或转移性胰腺癌患者,按1:1随机分配至TLP0-001联合S-1组或安慰剂联合S-1组,主要评价总生存期与安全性,试验遵循日本药物临床试验质量管理规范。

要点

  • 对象为对吉西他滨联合白蛋白结合型紫杉醇难治或不耐受的不可手术或转移性胰腺癌患者。
  • 计划入组185例,按1:1随机分为TLP0-001联合S-1组与安慰剂联合S-1组。
  • 主要目的为比较两组安全性及以总生存期衡量的疗效。

核心结论

  • 作者决定开展本研究以评价TLP0-001作为胰腺癌二线治疗的安全性与疗效,以期该新药在日本获得批准。
  • 该试验为TLP0-001首次人体临床试验,将在和歌山医科大学第二外科进行,直至中期分析确认安全性后计划在日本18家机构开展多中心试验。

研究设计与样本

  • 研究者发起的双盲对照试验,通过中央登记按动态分配以1:1比例将患者分入两组。
  • 计划纳入185例对吉西他滨联合白蛋白结合型紫杉醇标准一线化疗难治或不耐受的不可手术或转移性胰腺癌患者。
  • 患者分配至安慰剂联合S-1组(对照组)或TLP0-001联合S-1组(研究产品组)接受二线治疗。
  • 试验遵循日本药物临床试验质量管理规范实施。

关键数值与推荐

  • 主要目的为通过比较两组评价研究产品的安全性及以总生存期衡量的疗效。

局限性

  • 该试验为TLP0-001首次人体临床试验,仅在和歌山医科大学第二外科进行,直至中期分析确认安全性后才计划在日本18家机构开展多中心试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic cancer is a refractory malignancy, and the development of a new effective treatment strategy is needed. We generated a dendritic cell vaccine by culturing monocytes obtained by apheresis of blood from each patient, inducing their differentiation into dendritic cells, and pulsing with tumor antigen peptides. However, the clinical efficacy of the vaccine has not been established. We therefore decided to conduct an exploratory clinical trial of dendritic cell vaccine loaded with Wilms' tumor gene 1 peptides (TLP0-001) as a potential new treatment for patients with advanced pancreatic cancer refractory to standard chemotherapy. METHODS: This is an investigator-initiated, double-blind, comparative trial. The patients were allocated to two groups in a 1:1 ratio through a central registration by dynamic allocation. A total of 185 patients with inoperable or metastatic pancreatic cancer who were refractory or intolerant to standard primary chemotherapy with gemcitabine plus nab-paclitaxel will be allocated to secondary treatment either with placebo in combination with S-1 (the control group) or TLP0-001 in combination with S-1 (the investigational product group). The primary objective of this trial is to evaluate the safety and efficacy (as measured by overall survival) of the investigational product by comparing the two groups. This clinical trial will be performed in accordance with Japanese Good Clinical Practice guidelines. DISCUSSION: Clinical trials of the standard regimen, including gemcitabine, for advanced pancreatic cancer are ongoing worldwide. However, a strategy for after the primary treatment has not been established. We therefore decided to conduct this study to evaluate the safety and efficacy of TLP0-001 as a secondary treatment for pancreatic cancer in anticipation of the approval of this new drug in Japan. This trial is conducted with full consideration of safety, as it is the first-in-human clinical trial of TLP0-001; thus, the trial will be conducted only at the Second Department of Surgery at Wakayama Medical University until the safety is confirmed by interim analysis. We plan to conduct a multicenter trial at 18 institutions in Japan after confirmation of the safety. TRIAL REGISTRATION: University Hospital Medical Information Network Clinical Trials Registry, UMIN000027179 . Registered on 9 April 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Katsuda M, Miyazawa M, Ojima T, et al. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy. Trials. 2019. PMID: 31029154. doi:10.1186/s13063-019-3332-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。